Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Dec 6, 2007

PTC and Spinal Muscular Atrophy Foundation Extend Agreement

  • PTC Therapeutics and the Spinal Muscular Atrophy Foundation agreed to expand their research collaboration to identify and characterized compounds to treat the disease.

    PTC will receive an additional $1.6 million in funding when certain milestone considerations are met.

    The partnerhip is focusing on candidates to treat spinal muscular atrophy (SMA) by increasing production of the survival motor neuron (SMN) protein, the absence of which causes SMA.

    “By applying our proprietary technologies,” says Stuart W. Peltz, Ph.D., president and CEO of PTC, “we have made important progress in our efforts to identify treatments for SMA.”



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »